Abstract

Stroke remains a leading cause of death and disability worldwide. Despite continuous advances, the identification of key molecular signatures in the hyper-acute phase of ischemic stroke is still a primary interest for translational research on stroke diagnosis, prognosis, and treatment. Data integration from high-throughput -omics techniques has become crucial to unraveling key interactions among different molecular elements in complex biological contexts, such as ischemic stroke. Thus, we used advanced data integration methods for a multi-level joint analysis of transcriptomics and proteomics data sets obtained from mouse brains at 2 h after cerebral ischemia. By modeling net-like correlation structures, we identified an integrated network of genes and proteins that are differentially expressed at a very early stage after stroke. We validated 10 of these deregulated elements in acute stroke, and changes in their expression pattern over time after cerebral ischemia were described. Of these, CLDN20, GADD45G, RGS2, BAG5, and CTNND2 were next evaluated as blood biomarkers of cerebral ischemia in mice and human blood samples, which were obtained from stroke patients and patients presenting stroke-mimicking conditions. Our findings indicate that CTNND2 levels in blood might potentially be useful for distinguishing ischemic strokes from stroke-mimicking conditions in the hyper-acute phase of the disease. Furthermore, circulating GADD45G content within the first 6 h after stroke could also play a key role in predicting poor outcomes in stroke patients. For the first time, we have used an integrative biostatistical approach to elucidate key molecules in the initial stages of stroke pathophysiology and highlight new notable molecules that might be further considered as blood biomarkers of ischemic stroke.

Highlights

  • Highlights Multi-omics analyses of transcriptomics and proteomics data in the mouse ischemic brain

  • CLDN20, Growth arrest and DNA-damage-inducible protein GADD45 gamma (GADD45G), RGS2, BAG5, and CTNND2 were evaluated as blood biomarkers of cerebral ischemia in mice and human blood samples, which were obtained from stroke patients and patients presenting stroke-mimicking conditions

  • With the translational aim of identifying potential stroke biomarkers, this study has applied an integrative analysis of massive transcriptomics and proteomics data compiled from mouse brains very acutely after cerebral ischemia

Read more

Summary

Introduction

Highlights Multi-omics analyses of transcriptomics and proteomics data in the mouse ischemic brain. Our findings indicate that CTNND2 levels in blood might potentially be useful for distinguishing ischemic strokes from stroke-mimicking conditions in the hyper-acute phase of the disease. Blood biomarkers might accelerate stroke treatment, help with patient monitoring for adverse effects, and help to anticipate poor patient prognoses at later stages of the disease [11, 12]. With this goal, better characterization of the stroke pathophysiology is required to facilitate the identification of molecular indicators of ischemic stroke and provide novel insights into potential therapeutic targets. Such efforts could help to restrain or even reverse the progression of ischemic damage

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call